Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Chemo-immuno combination shows improved PFS when compared with sole chemotherapy treatment in advanced breast cancer

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.18
Views: 838
Rating:

Prof Leisha Emens - Johns Hopkins Kimmel Cancer, Baltimore, USA

Prof Leisha Emens speaks to ecancer at SABCS 2018 about the IMpassion130 trial comparing a chemotherapy-immunotherapy combination and chemotherapy in patients with untreated metastatic or locally advanced unresectable triple negative breast cancer.

Prof Emens reports that treatment with the chemo-immuno combination of atezolizumab with nab-paclitaxel showed a statistically significant improvement in progression free survival, particularly in the PD-L1 positive group where an improvement of 2.5 months was seen.

She believes these findings to be very important as triple negative breast cancer has previously only been treated with chemotherapy yet now immunotherapy as an addition is showing an overall survival benefit.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation